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Abstract
Background: The antimicrobial peptides human b-defensin 1 and 2 (hBD-1 and 2) and the cathelicidin LL-37yhCAP-18 are
key factors in innate immune responses of the respiratory tract. The aim of this study was to determine the concentrations of
these peptides in airway surface fluid of CF patients with mild lung disease. Methods: We measured the concentrations of hBD-
1, hBD-2, and LL-37 in bronchoalveolar lavage fluid of 20 patients (5–34 years) participating in the prospective BEAT-study
(bronchoalveolar lavage for the evaluation of anti-inflammatory treatment) using an immuno-dot blot-assay. Results: All three
peptides could be detected in lavage fluid of the study population. Increased levels of inflammatory markers in bronchoalveolar
lavage fluid were associated with elevated concentrations of LL-37yhCAP-18 (total cell count, Ps0.006; relative neutrophil
count, Ps0.002). Deterioration of lung function, measured by MEF (maximal flow rate at 25% of residual forced vital25
capacity), correlated with decreased hBD-2 (Ps0.026), but increased LL-37yhCAP-18 concentrations (Ps0.016). Conclusions:
The data suggest that concentrations of antimicrobial peptides are correlated with severity of CF lung disease: Levels of LL-37y
hCAP-18 are associated with bronchial inflammation and, therefore disease severity, whereas decreased levels of b-defensins in
advanced lung disease likely contribute to a secondary defect of the local host defense.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cystic fibrosis (CF) is the most common autosomal
recessive disorder in the Caucasian population and is
caused by mutations in the gene coding for the CF
transmembrane conductance regulator (CFTR) w1x.
There is evidence of bronchial inflammation and bacte-
 The study was supported by a grant from Mukoviszidose e. V.
and by Hoffmann-La Roche to K. Paul, by the Friedrich-Baur-Stiftung
(0066y2000) and the Deutsche Forschungsgemeinschaft (Ba 1641y3
and 1641y5) to R. Bals, and by grants of the Sanitatsrat Dr A.¨
Huebner Stiftung and of the Deutsche Gesellschaft fur Padiatrische¨¨
Infektiologie to S. Schaller-Bals.
1The authors Christiane I.U. Chen and Susanne Schaller-Bals
contributed equally.
*Corresponding author. Tel.:q49-6421-286-4994; fax:q49-6421-
28-68987.
E-mail address: bals@mailer.uni-marburg.de (R. Bals).
rial colonization even before the onset of clinically overt
lung disease w2x, pointing to a primarily inherited mod-
ulation of immune response rather than a defect, which
occurs secondarily with progression of the disease.
b-defensins and cathelicidins are the two principal
families of antimicrobial peptides expressed in the epi-
thelium of the human lung and include the human b-
defensins 1 to 4 (hBD-1 to hBD-4) w3–10x and the
cathelicidin LL-37yhCAP-18 w11–13x. LL-37yhCAP-18
is expressed as pre-pro-peptide. The propeptide is called
hCAP-18 and stored in cells. After secretion, the pro-
piece is cleaved off and the C-terminal peptide is called
LL-37. LL-37 is the active peptide with antimicrobial
and multiple other activities w14x. Antimicrobial peptides
contribute to innate immunity by direct antimicrobial
activity w15x. Additionally, defensins and LL-37yhCAP-
18 have multiple other functions, such as the activation
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Table 1
Patients’ characteristics
BAL 1 (ns20) BAL 2 (ns20) BAL 3 (ns14)
Median (95% CI) Median (95% CI) Median (95% CI)
Age (years) 11 (9–14) 13 (10–16) 14 (11–15)
FEV (% pred.)1 97 (93–101) 88 (83–103) 91 (78–101.5)
MEF (% pred.)25 58 (45–72) 42 (28–72) 55 (27–67)
Cellular viability pooled fraction (%) 88 (80–92) 82 (76–86) 83 (78–86)
Cell count pooled fraction 20 (14–51) 24 (16–46) 42 (19–66)
(=10 yml)4
Neutrophils pooled fraction (%) 22 (0.8–89) 32 (0.20–92) 56 (0.70–94)
Positive for Staphylococcus 13 patients 9 patients 7 patients
aureus (BAL)
Positive for Pseudomonas 7 patients 6 patients 5 patients
aeruginosa (BAL)
Positive for Staphylococcus 2 patients 2 patients 2 patients
aureus and Pseudomonas
aeruginosa (BAL)
FEV sforced expiratory volume in one second, MEF smaximal flow rate at 25% of remaining forced vital capacity. Some patients were not1 25
colonized of colonized with more than one species.
of inflammatory cells, the regulation of adaptive immu-
nity w16,17x, and the induction of angiogenesis w18x.
The role of antimicrobial peptides in the pathogenesis
of cystic fibrosis lung disease is unclear. In the high salt
hypothesis of Welsh and colleagues w19x, the activity of
antimicrobial peptides is inhibited by the high salt
concentration in CF airway surface fluid. Other reports
indicate that the salt-independent antimicrobial activity
of CF airway surface fluid is decreased w20x. Defensins
and the cathelicidin also may exert proinflammatory or
cytotoxic effects on airway epithelial cells as has been
proposed for a-defensins found in lavage fluid of CF
patients w21x. Polymorphisms of the genes coding for
defensins are associated with susceptibility to Candida
carriage in type I diabetes and with the clinical course
of chronic obstructive pulmonary disease w22x. These
association studies support the role of defensins in host
defense and inflammation. Based on their host defense
and proinflammatory functions, antimicrobial peptides
likely have a central role in the pathogenesis of CF lung
disease.
It was the aim of this study to measure concentrations
of hBD-1, hBD-2, and LL-37yhCAP-18 in bronchoal-
veolar lavage fluid of CF patients with early mild lung
disease. We hypothesized that peptide concentrations
correlate with colonization status, pulmonary functions
parameters, or inflammatory markers in bronchioalveolar
lavage fluid (BALF).
2. Material and methods
2.1. Patients
Flexible fiber optic bronchoscopy and bronchoalveo-
lar lavage (BAL) were performed three times within
three years (time interval 18 months) in CF patients
(5–34 years) during the course of the BEAT-study
(bronchoalveolar lavage for the evaluation of anti-
inflammatory treatment) w23x. Twenty patients took part
at the first BAL, 20 at the second BAL (18 months),
and 14 at the third BAL (36 months) (Table 1). All
patients were free of infectious exacerbations within 6
weeks before BAL. Informed consent had been given
by each patientythe parents before the procedure, which
was approved by the local Ethics Committee. Measure-
ments of pulmonary function tests were performed
according to current guidelines w24x. Bacterial cultures
were obtained in 2 ml of the pooled BALF sample prior
to processing.
2.2. Flexible fiber optic bronchoscopy and BAL
BAL was performed at 08.00 h. No rhDNAse was
inhaled before the procedure, but b2-agonists were
permitted. No patient received inhaled steroids or amino
glycosides. Flexible fiber optic bronchoscopy (Olympus,
external diameter 3.5 or 4.9 mm, Hamburg, Germany)
and BAL were performed in deep sedation according to
standard methods w23x. The first and pooled (second
and following) fractions were analyzed separately, only
the pooled fraction was used in this investigation. Total
cell count of the BAL was measured by two experienced
laboratory assistants, the cell differentials by an experi-
enced cytopathologist, who counted at least 500 cells in
each preparation.
2.3. Measurement of concentrations of antimicrobial
peptides
Concentrations of hBD-1, hBD-2, and LL-37yhCAP-
18 in BALF were measured as described previously
w20,25,26x. In brief, after centrifugation of BALF at
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Fig. 1. Western blots of airway surface fluid showing bands repre-
senting mature peptides for hBD-1, hBD-2, and LL-37. Lung lavage
fluid of arbitrarily selected patients was extracted in acetonitrile (final
concentration 60%) and trifluoroacetic acid (TFA, final concentration
1%) overnight at room temperature. After centrifugation and lyophil-
ization, the material was applied to Western blotting. 20 or 40 ng of
synthetic peptide, Sssample.
1000 g for 20 min, 2 ml of each sample were dotted
onto a nitrocellulose membrane, immunolabeled with
polyclonal rabbit antibodies to hBD-1, hBD-2 and LL-
37yhCAP-18 (dilution 1:1000), followed by a peroxi-
dase-conjugated anti-rabbit antibody from goat (Sigma
Chemical Co., 1:5000). Antibodies against the antimi-
crobial peptides were generated by performing a stan-
dard immunization protocol in rabbits w9,11x, and tested
for specificity to the corresponding antimicrobial pep-
tide. Comparisons of the immune- with the pre-immune-
sera in blotting experiments showed specific reactivity
of the polyclonal antibodies to their corresponding pep-
tides (data not shown). Additionally, the assays were
tested by addition of a known amount of peptides to
BALF and measuring the increase of peptide concentra-
tions. The measurements showed the expected change
in concentration. After the washes, bound antibodies
were visualized by using chemiluminescent substrate
(ECL – enhanced chemiluminescence-Western blotting
detection kit; Amersham, Arlington Heights, IL) and
exposure to X-ray films. Signal intensity was analyzed
using a GelDoc 2000 system (Biorad, Munich, Germa-
ny). To characterize the molecular forms of the peptides
in airway secretion, we prepared Western blots of lavage
fluid from selected patients as described before using
chemically synthesized peptides as standards (defensins
from IPF Pharmaceuticals, Hanover; LL-37 from Dr
Henklein, Charite, Berlin, Germany).´
2.4. Statistical analysis
Data of the three BAL’s were pooled. Group median
of numerical data were tested for significant differences
by the Mann–Whitney U-Wilcoxon rank sum W test,
correlations by the Spearman correlation test with two-
tailed level of significance. All levels of significance
were set at PF0.05.
3. Results
3.1. Mucosal antimicrobial peptides are present in air-
way secretion of CF patients with mild lung disease
To determine whether antimicrobial peptides are pres-
ent in the airways of CF patients with mild lung disease,
we analyzed bronchioalveolar lavage fluid by antigen
capture assay and Western blot. The antigen capture
assay was validated earlier to measure the amounts of
peptides in human body fluids and reached a sensitivity
of 5 ngyml w9,11,20x. We first addressed the question,
whether mucosal antimicrobial peptides are present in
airways of patients with CF, and identified detectable
amounts of hBD-1, hBD-2, and LL-37yhCAP-18 in
BALF from patients of different ages and degrees of
lung disease. The concentrations of the peptides are in
the range from undetectable to 15 mgyml. To character-
ize the molecular structures of the peptides in airway
secretion, we performed Western blot analysis and
immunopositive bands representing mature peptides
were identified (Fig. 1).
3.2. Levels of antimicrobial peptides correlate with
disease severity
We next asked whether levels of antimicrobial pep-
tides correlate with markers of inflammation in the
BALF, microbiological data, or pulmonary function tests.
Data were correlated with levels of antimicrobial pep-
tides in a cross sectional analysis.
With increasing levels of inflammatory markers (total
cell count and relative neutrophil count) the concentra-
tion of LL-37yhCAP-18 increased (Table 2 and Fig.
2a,b). hBD-1 and hBD-2 correlated positively with each
other, while they did not show a correlation with LL-37
(Table 2).
Deterioration of lung function as measured by
MEF was associated with increased LL-37yhCAP-1825
and lower levels of hBD-2 (Table 2 and Fig. 3a,b).
Presence of bacteria was not associated with signifi-
cantly increased levels of antimicrobial peptides in the
study population. There were no significant changes of
the concentrations of the antimicrobial peptides during
the study in a longitudinal analysis. The data represent
a cross-sectional analysis.
4. Discussion
The results of our study demonstrate that the antimi-
crobial peptides hBD-1, hBD-2 and LL-37yhCAP-18
are present in BALF of patients with CF. The main
finding is that levels of these peptides are associated
with pulmonary inflammation and disease severity. The
concentration of the cathelicidin LL-37yhCAP-18
increases with lung inflammation, as judged by neutro-
phil airway inflammation. In contrast, the levels of hBD-
1 and hBD-2 are not changed by endobronchial
inflammation. Disease severity as estimated by reduced
lung function is associated with increased levels of LL-
37, whereas concentrations of hBD-2 are decreased. The
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Table 2
Correlation of the antimicrobial peptides with inflammatory parameters in BALF (with correlation coefficient ‘r’ and, in parenthesis point of
significance ‘P’)
FEV1 MEF25 Total cell Relative hBD-1 hBD-2
count neutrophil count
hBD-1 0.200 0.266 y0.051 y0.125 – –
(0.148) (0.052) (0.714) (0.374)
hBD-2 0.144 0.3020 y0.024 y0.180 0.417 –
(0.299) (0.026) (0.862) (0.896) 0.002
LL-37 y0.261 y0.326 0.370 0.414 y0.224 y0.037
(0.057) (0.016) (0.006) (0.002) 0.103 0.791
Bold printed are the significant correlations with PF0.05.
Fig. 2. Concentrations of LL-37 are correlated with pulmonary inflammation. Levels of LL-37 increase with elevated numbers of total cellsyml
(a) or relative neutrophil count (b).
Fig. 3. Concentrations of LL-37 and hBD-2 are correlated with pulmonary function. With decreased MEF the levels of LL-37 in BALF increase25
(a), whereas concentrations of hBD-2 are decreased (b).
concentrations of antimicrobial peptides in the present
study are equivalent to the levels described in other
pathologies w26–28x. We were not able to detect a
longitudinal change of the peptide concentrations during
the course of the study in individual patients. This is
likely caused by the limited number of patients and the
relatively short duration of the study. A small number
of patients did not undergo the third BAL. These patients
likely had more severe lung disease. This could possibly
result in underestimation of the effects demonstrated in
the study.
An early step in the development of CF lung disease
is the incapability of the local host defense system to
clear the bacterial colonization and inflammation, which
might be linked to the absence or inhibition of antimi-
crobial substances w29x. Antimicrobial peptides like
hBD-1, hBD-2, and LL-37yhCAP-18 play an important
role in innate and adaptive immunity. The antimicrobial
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activity of airway epithelial cells from CF patients is
decreased as compared to non-CF cells w7,19,20x. The
nature of this defect remained largely speculative. One
hypothesis stated that the salt concentration of CF airway
secretions is increased and that this results in inactivation
of antimicrobial substances w19x. Another hypothesis
described defects in secretion of antimicrobial factors
w20x. Lacking appropriate methods to sample airway
surface liquid from patients it has not been possible to
verify or falsify these hypotheses. The concentrations of
these peptides in mild CF lung disease and their corre-
lation with disease severity have been unknown. The
present study shows that b-defensins and LL-37yhCAP-
18 are present in this patient group, and alterations of
their levels are associated with disease severity. The
cathelicidin LL-37yhCAP-18 is associated with airway
inflammation and disease severity as determined from
pulmonary function parameters. Its production by epi-
thelial cells, neutrophils, and macrophages w11–13,30x
contributes to the amount of peptide detected in BALF.
Beside its direct antimicrobial function, LL-37 binds to
formyl peptide receptor like 1 (FPRL1), and chemoat-
tracts human peripheral blood neutrophils, monocytes,
and T cells w31x. Increased concentrations of LL-37y
hCAP-18 in the airway lumen likely result in the
recruitment of further inflammatory cells.
In contrast to LL-37yhCAP-18, concentrations of b-
defensins were found decreased in patients with more
impaired lung function. Several explanations may
account for this finding: (1) Chronic airway inflamma-
tion results in damage and loss of epithelial cells that
secrete most of the b-defensins; (2) Chronic inflamma-
tion differs significantly from acute responses and results
in down regulation of several molecules involved in
inflammation and host defense, possibly also of b-
defensins w32x. Furthermore, it is possible that microor-
ganisms actively down regulate the synthesis, secretion
andyor expression of certain antimicrobial peptides w33x;
and (3) the increased load of luminal proteases could
result in fastened cleavage and inactivation of defensins.
As an example, the metalloproteinase matrilysin (MMP-
7) has been described to be increased in CF airways
w34x, and is able to cleave defensins w35x. The relatively
lower concentrations of b-defensins during advanced
stages of CF lung disease likely contribute to a second-
ary defect of the host defense altering the natural history
of the disease. It would be interesting to correlate the
altered concentrations of the peptides with functional
assays. Due to the small amount of material and the
dilution of the BAL samples it was not possible to
perform functional assays such as antimicrobial or cell
physiological tests.
In conclusion, mucosal antimicrobial peptides are
present in mild CF lung disease. Alterations of their
concentrations are associated with disease severity indi-
cating a link to the mechanisms of lung destruction. LL-
37yhCAP-18 is a marker for the degree of
bronchoalveolar inflammation, whereas concentrations
of b-defensins are lower in more advanced lung disease.
Since antimicrobial peptides act in a concentration-
dependent manner, therapeutic modifications (inhibition
or augmentation) could be regarded as a feasible alter-
native approach to treatment of CF.
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